Aytu BioPharma, Inc.
AYTU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $13,888 | $15,135 | $18,452 | $16,221 |
| % Growth | -8.2% | -18% | 13.8% | – |
| Cost of Goods Sold | $4,702 | $4,881 | $5,646 | $5,435 |
| Gross Profit | $9,186 | $10,254 | $12,806 | $10,786 |
| % Margin | 66.1% | 67.8% | 69.4% | 66.5% |
| R&D Expenses | $0 | $216 | $162 | $522 |
| G&A Expenses | $4,924 | $3,696 | $4,109 | $4,449 |
| SG&A Expenses | $10,246 | $8,477 | $9,303 | $9,721 |
| Sales & Mktg Exp. | $5,322 | $4,781 | $5,194 | $5,272 |
| Other Operating Expenses | $444 | $9,184 | $920 | $2,238 |
| Operating Expenses | $10,690 | $17,877 | $10,385 | $12,481 |
| Operating Income | -$1,504 | -$7,623 | $2,421 | -$1,695 |
| % Margin | -10.8% | -50.4% | 13.1% | -10.4% |
| Other Income/Exp. Net | $3,469 | -$11,820 | $1,397 | $2,077 |
| Pre-Tax Income | $1,965 | -$19,443 | $3,818 | $382 |
| Tax Expense | $0 | $437 | -$122 | -$283 |
| Net Income | $1,965 | -$19,818 | $3,994 | $788 |
| % Margin | 14.1% | -130.9% | 21.6% | 4.9% |
| EPS | -0.08 | -2.92 | 0.65 | 0.02 |
| % Growth | 97.3% | -549.2% | 3,150% | – |
| EPS Diluted | -0.08 | -2.92 | 0.21 | -0.26 |
| Weighted Avg Shares Out | 9,441 | 6,792 | 6,135 | 6,132 |
| Weighted Avg Shares Out Dil | 19,477 | 6,792 | 8,204 | 8,485 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $516 | $730 | $900 | $1,079 |
| Depreciation & Amortization | $803 | $1,294 | $1,317 | $1,173 |
| EBITDA | $3,284 | -$17,419 | $6,035 | $2,634 |
| % Margin | 23.6% | -115.1% | 32.7% | 16.2% |